Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 5

Augmentation treatment in major depressive disorder: focus on aripiprazole

Authors J Craig Nelson, Andrei Pikalov, Robert M Berman

Published Date August 2008 Volume 2008:4(5) Pages 937—948

DOI http://dx.doi.org/10.2147/NDT.S3369

Published 11 August 2008

J Craig Nelson1, Andrei Pikalov2, Robert M Berman3

1University of California San Francisco, San Francisco, California, USA; 2Otsuka Pharmaceutical Inc., Rockville, MD, USA; 3Bristol-Myers Squibb, Wallingford, CT, USA

Abstract: Major depressive disorder (MDD) is a disabling psychiatric condition for which effective treatment remains an outstanding need. Antidepressants are currently the mainstay of treatment for depression; however, almost two-thirds of patients will fail to achieve remission with initial treatment. As a result, a range of augmentation and combination strategies have been used in order to improve outcomes for patients. Despite the popularity of these approaches, limited data from double-blind, randomized, placebo-controlled studies are available to allow clinicians to determine which are the most effective augmentation options or which patients are most likely to respond to which options. Recently, evidence has shown that adjunctive therapy with atypical antipsychotics has the potential for beneficial antidepressant effects in the absence of psychotic symptoms. In particular, aripiprazole has shown efficacy as an augmentation option with standard antidepressant therapy in two, large, randomized, double-blind studies. Based on these efficacy and safety data, aripiprazole was recently approved by the FDA as adjunctive therapy for MDD. The availability of this new treatment option should allow more patients with MDD to achieve remission and, ultimately, long-term, successful outcomes.

Keywords: major depression, antipsychotic, mood disorder, aripiprazole

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

Berman R, Thase M, Trivedi M, Hazel JA, Marler S, McQuade R, Carson W, Baker R, Marcus R

Neuropsychiatric Disease and Treatment 2011, 7:303-312

Published Date: 24 May 2011

Readers of this article also read:

Acute effects of single and multiple level thoracic manipulations on chronic mechanical neck pain: a randomized controlled trial

Puntumetakul R, Suvarnnato T, Werasirirat P, Uthaikhup S, Yamauchi J, Boucaut R

Neuropsychiatric Disease and Treatment 2015, 11:137-144

Published Date: 12 January 2015

Engineered collagen hydrogels for the sustained release of biomolecules and imaging agents: promoting the growth of human gingival cells

Choi J, Park H, Kim T, Jeong Y, Oh MH, Hyeon T, Gilad AA, Lee KH

International Journal of Nanomedicine 2014, 9:5189-5201

Published Date: 11 November 2014

xCELLigence system for real-time label-free monitoring of growth and viability of cell lines from hematological malignancies

Martinez-Serra J, Gutierrez A, Muñoz-Capó S, Navarro-Palou M, Ros T, Amat JC, Lopez B, Marcus TF, Fueyo L, Suquia AG, Gines J, Rubio F, Ramos R, Besalduch J

OncoTargets and Therapy 2014, 7:985-994

Published Date: 12 June 2014

Manganese-containing Prussian blue nanoparticles for imaging of pediatric brain tumors

Dumont MF, Yadavilli S, Sze RW, Nazarian J, Fernandes R

International Journal of Nanomedicine 2014, 9:2581-2595

Published Date: 23 May 2014

Dengue: factors driving the emerging epidemic

Ali M

Clinical Epidemiology 2013, 5:461-463

Published Date: 19 November 2013

Luminescent single-walled carbon nanotube-sensitized europium nanoprobes for cellular imaging

Avti PK, Sitharaman B

International Journal of Nanomedicine 2012, 7:1953-1964

Published Date: 17 April 2012

Gold nanoparticle trapping and delivery for therapeutic applications

Aziz MS, Suwanpayak N, Jalil MA, Jomtarak R, Saktioto T, Ali J, Yupapin PP

International Journal of Nanomedicine 2012, 7:11-17

Published Date: 29 December 2011

Amino acid-responsive Crohn's disease: a case study

Alvin Stein, Marty Hinz, Thomas Uncini

Clinical and Experimental Gastroenterology 2010, 3:171-177

Published Date: 6 December 2010

Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia

Andrew Thomson

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 30 June 2005